Immunotherapy of cancer: Reprogramming tumor-immune crosstalk

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Payne, Kyle K ^a   Toor, Amir A ^b   Wang, Xiang Yang ^a   Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; EPIGENETICS; HUMAN; IMMUNITY; IMMUNOMODULATION; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; TUMOR ESCAPE;

TUMOR ANTIGEN;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR ESCAPE;

EID: 84868686391     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/760965     Document Type: Review

References (87)

1. Cobleigh M. A., Other options in the treatment of advanced breast cancer. Seminars in Oncology 2011 38 supplement 2 S11 S16 2-s2.0-79956210767 10.1053/j.seminoncol.2011.04.005
2. Johnston S. R., The role of chemotherapy and targeted agents in patients with metastatic breast cancer. European Journal of Cancer 2011 47 supplement 3 S38 S47
3. Berry J., Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clinical Therapeutics 2005 27 11 1671 1684 2-s2.0-29144506097 10.1016/j.clinthera.2005.11.013 (Pubitemid 41815221)
4. Markopoulos C. J., Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. Cancer and Metastasis Reviews 2010 29 4 581 594 2-s2.0-78449298655 10.1007/s10555-010-9248-x
5. Brewster A. M., Hortobagyi G. N., Broglio K. R., Kau S. W., Santa-Maria C. A., Arun B., Buzdar A. U., Booser D. J., Valero V., Bondy M., Esteva F. J., Residual risk of breast cancer recurrence 5 years after adjuvant therapy. Journal of the National Cancer Institute 2008 100 16 1179 1183 2-s2.0-51049084866 10.1093/jnci/djn233
6. Benson J. R., Jatoi I., Keisch M., Esteva F. J., Makris A., Jordan V. C., Early breast cancer. The Lancet 2009 373 9673 1463 1479 2-s2.0-64949128193 10.1016/S0140-6736(09)60316-0
7. Curigliano G., Spitaleri G., Petri E., Rescigno M., de Braud F., Cardillo A., Munzone E., Rocca A., Bonizzi G., Brichard V., Orlando L., Goldhirsch A., Breast cancer vaccines: a clinical reality or fairy tale? Annals of Oncology 2006 17 5 750 762 2-s2.0-33646170120 10.1093/annonc/mdj083
8. Zhou J., Zhong Y., Breast cancer immunotherapy. Cellular & Molecular Immunology 2004 1 4 247 255 2-s2.0-33644836561
9. Ladjemi M. Z., Jacot W., Chardès T., Pèlegrin A., Navarro-Teulon I., Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunology, Immunotherapy 2010 59 9 1295 1312 2-s2.0-77956070565 10.1007/s00262-010-0869-2
10. + T cells persist, mediate tumor regression, and acquire central memory phenotype. Proceedings of the National Academy of Sciences of the United States of America 2012 109 12 4592 4597 10.1073/pnas.1113748109
11. Le H. K., Graham L., Miller C. H., Kmieciak M., Manjili M. H., Bear H. D., Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunology, Immunotherapy 2009 58 10 1565 1576 2-s2.0-68549106145 10.1007/s00262-009-0666-y
12. Tuve S., Chen B. M., Liu Y., Cheng T. L., Touré P., Sow P. S., Feng Q., Kiviat N., Strauss R., Ni S., Li Z. Y., Roffler S. R., Lieber A., Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Research 2007 67 12 5929 5939 2-s2.0-34250871751 10.1158/0008-5472.CAN-06-4296 (Pubitemid 46985029)
13. Bernhard H., Neudorfer J., Gebhard K., Conrad H., Hermann C., Nährig J., Fend F., Weber W., Busch D. H., Peschel C., Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunology, Immunotherapy 2008 57 2 271 280 2-s2.0-36348942363 10.1007/s00262-007-0355-7 (Pubitemid 350159915)
14. Morales J. K., Kmieciak M., Graham L., Feldmesser M., Bear H. D., Manjili M. H., Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy 2009 58 6 941 953 2-s2.0-63949088142 10.1007/s00262-008-0609-z
15. Kmieciak M., Basu D., Payne K. K., Toor A., Yacoub A., Wang X. Y., Smith L., Bear H. D., Manjili M. H., Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. Journal of Immunology 2011 187 2 708 717 2-s2.0-79960549766 10.4049/jimmunol.1100502
16. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research 2001 61 12 4766 4772 2-s2.0-0035874949 (Pubitemid 32691889)
17. Stagg J., Divisekera U., McLaughlin N., Sharkey J., Pommey S., Denoyer D., Dwyer K. M., Smyth M. J., Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 2010 107 4 1547 1552 2-s2.0-75949112218 10.1073/pnas.0908801107
18. Bergmann C., Strauss L., Wang Y., Szczepanski M. J., Lang S., Johnson J. T., Whiteside T. L., T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clinical Cancer Research 2008 14 12 3706 3715 2-s2.0-52449125138 10.1158/1078-0432.CCR-07-5126
19. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. Journal of Experimental Medicine 1998 188 2 287 296 2-s2.0-0031821875 10.1084/jem.188.2.287 (Pubitemid 28357757)
20. + T cells: a common basis between tumor immunity and autoimmunity. Journal of Immunology 1999 163 10 5211 5218 2-s2.0-0033571105
21. + natural suppressor cells. International Journal of Cancer 1997 74 69 74 (Pubitemid 27157858)
22. Bingle L., Brown N. J., Lewis C. E., The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology 2002 196 3 254 265 2-s2.0-0036187615 10.1002/path.1027 (Pubitemid 34189413)
23. Diaz-Montero C. M., Salem M. L., Nishimura M. I., Garrett-Mayer E., Cole D. J., Montero A. J., Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology, Immunotherapy 2009 58 1 49 59 2-s2.0-54849440346 10.1007/s00262-008-0523-4
24. Mundy-Bosse B. L., Thornton L. M., Yang H. C., Andersen B. L., Carson W. E., Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cellular Immunology 2011 270 1 80 87 2-s2.0-79959852117 10.1016/j.cellimm.2011.04.003
25. Filipazzi P., Huber V., Rivoltini L., Phenotype, function and clinical implication of myeloid-derived suppressor cell in cancer patients. Cancer Immunology, Immunotherapy 2012 61 255 263 10.1007/s00262-011-1161-9
26. Ohki S., Shibata M., Gonda K., Machida T., Shimura T., Nakamura I., Ohtake T., Koyama Y., Suzuki S., Ohto H., Takenoshita S., Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncology Reports 2012 28 2 453 458
27. Terabe M., Matsui S., Park J. M., Mamura M., Noben-Trauth N., Donaldson D. D., Chen W., Wahl S. M., Ledbetter S., Pratt B., Letterio J. J., Paul W. E., Berzofsky J. A., Transforming growth factor- β production and myeloid cells are an effector mechanism through Which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. Journal of Experimental Medicine 2003 198 11 1741 1752 2-s2.0-10744220561 10.1084/jem.20022227 (Pubitemid 37494166)
28. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of Immunology 2004 172 2 989 999 2-s2.0-1642536454 (Pubitemid 38113758)
29. Viola A., Bronte V., Metabolic mechanisms of cancer-induced inhibition of immune responses. Seminars in Cancer Biology 2007 17 4 309 316 2-s2.0-34547692958 10.1016/j.semcancer.2007.06.005 (Pubitemid 47211961)
30. Corzo C. A., Cotter M. J., Cheng P., Cheng F., Kusmartsev S., Sotomayor E., Padhya T., McCaffrey T. V., McCaffrey J. C., Gabrilovich D. I., Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. Journal of Immunology 2009 182 9 5693 5701 2-s2.0-66949145484 10.4049/jimmunol.0900092
31. Youn J. I., Nagaraj S., Collazo M., Gabrilovich D. I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology 2008 181 8 5791 5802 2-s2.0-54049134747
32. Greten T. F., Manns M. P., Korangy F., Myeloid derived suppressor cells in human diseases. International Immunopharmacology 2011 11 7 802 807 2-s2.0-79955723632 10.1016/j.intimp.2011.01.003
33. Nagaraj S., Collazo M., Corzo C. A., Youn J. I., Ortiz M., Quiceno D., Gabrilovich D. I., Regulatory myeloid suppressor cells in health and disease. Cancer Research 2009 69 19 7503 7506 2-s2.0-70350218860 10.1158/0008-5472.CAN- 09-2152
34. Kmieciak M., Morales J. K., Morales J., Bolesta E., Grimes M., Manjili M. H., Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunology, Immunotherapy 2008 57 9 1391 1398 2-s2.0-45849098275 10.1007/s00262-008-0475-8
35. Moulis S., Sgroi D. C., Re-evaluating early breast neoplasia. Breast Cancer Research 2008 10 1, article 302 2-s2.0-44849113197 10.1186/bcr1853
36. Lakhani S. R., The transition from hyperplasia to invasive carcinoma of the breast. The Journal of Pathology 1999 187 272 278 (Pubitemid 29064150)
37. Habibi M., Kmieciak M., Graham L., Morales J. K., Bear H. D., Manjili M. H., Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Research and Treatment 2009 114 3 423 431 2-s2.0-61449147270 10.1007/s10549-008-0024-3
38. Liu Y., Lai L., Chen Q., Song Y., Xu S., Ma F., Wang X., Wang J., Yu H., Cao X., Wang Q., MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. The Journal of Immunology 2012 188 11 5500 5510 10.4049/jimmunol.1103505
39. Youn J. I., Collazo M., Shalova I. N., Biswas S. K., Gabrilovich D. I., Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Journal of Leukocyte Biology 2012 91 1 167 181
40. Kaufman H. L., Kim D. W., Deraffele G., Mitcham J., Coffin R. S., Kim-Schulze S., Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Annals of Surgical Oncology 2010 17 3 718 730 2-s2.0-77149141965 10.1245/s10434-009-0809-6
41. Meyer C., Sevko A., Ramacher M., Bazhin A. V., Falk C. S., Osen W., Borrello I., Kato M., Schadendorf D., Baniyash M., Umansky V., Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America 2011 108 41 17111 17116
42. hi and overexpress CD80, CD83, and DC-sign. Cancer Research 2010 70 11 4335 4345 2-s2.0-77953141534 10.1158/0008-5472.CAN-09-3767
43. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of Clinical Oncology 2007 25 18 2546 2553 2-s2.0-34447258415 10.1200/JCO.2006.08.5829 (Pubitemid 47041228)
44. Ko H. J., Lee J. M., Kim Y. J., Kim Y. S., Lee K. A., Kang C. Y., Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. Journal of Immunology 2009 182 4 1818 1828 2-s2.0-61449220940 10.4049/jimmunol.0802430
45. Mussai F., De Santo C., Cerundolo V., Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities. Journal of Immunotherapy 2012 35 6 449 459
46. Simpson A. J. G., Caballero O. L., Jungbluth A., Chen Y. T., Old L. J., Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer 2005 5 8 615 625 2-s2.0-23144464171 10.1038/nrc1669 (Pubitemid 41081387)
47. Van Der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 5038 1643 1647 2-s2.0-0026322151 (Pubitemid 21917508)
48. + T cells against NY-ESO-1. New England Journal of Medicine 2008 358 25 2698 2703 2-s2.0-45549099784 10.1056/NEJMoa0800251 (Pubitemid 351860862)
49. Meklat F., Li Z., Wang Z., Zhang Y., Zhang J., Jewell A., Lim S. H., Cancer-testis antigens in haematological malignancies. British Journal of Haematology 2007 136 6 769 776 2-s2.0-33847353863 10.1111/j.1365-2141.2006. 06484.x (Pubitemid 46348406)
50. Mischo A., Kubuschok B., Ertan K., Preuss K. D., Romeike B., Regitz E., Schormann C., De Bruijn D., Wadle A., Neumann F., Schmidt W., Renner C., Pfreundschuh M., Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. International Journal of Cancer 2006 118 3 696 703 2-s2.0-30444454959 10.1002/ijc.21352 (Pubitemid 43076020)
51. Badovinac-Crnjevic T., Spagnoli G., Juretic A., High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Medical Oncology 2012 29 3 1586 1591 10.1007/s12032-011-0120-9
52. Sugita Y., Wada H., Fujita S., NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Research 2004 64 2199 2204 10.1158/0008-5472.CAN-03-3070 (Pubitemid 38339473)
53. Scanlan M. J., Gure A. O., Jungbluth A. A., Old L. J., Chen Y. T., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunological Reviews 2002 188 22 32 2-s2.0-0036813331 10.1034/j.1600-065X. 2002.18803.x (Pubitemid 35398862)
54. + T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer 2007 120 11 2411 2417 2-s2.0-34247364939 10.1002/ijc.22376 (Pubitemid 46642128)
55. Fang F., Balch C., Schilder J., Breen T., Zhang S., Shen C., Li L., Kulesavage C., Snyder A. J., Nephew K. P., Matei D. E., A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010 116 17 4043 4053 2-s2.0-77954121574 10.1002/cncr.25204
56. Guo J. U., Su Y., Zhong C., Ming G. L., Song H., Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 2011 10 16 2662 2668 10.4161/cc.10.16.17093
57. Bird A., DNA methylation patterns and epigenetic memory. Genes and Development 2002 16 1 6 21 2-s2.0-0036144048 10.1101/gad.947102 (Pubitemid 34049633)
58. Ushijima T., Detection and interpretation of altered methylation patterns in cancer cells. Nature Reviews Cancer 2005 5 3 223 231 2-s2.0-14644396228 10.1038/nrc1571 (Pubitemid 40314953)
59. Ascierto M. L., Kmieciak M., Idowu M. O., Manjili R., Zhao Y., Grimes M., Dumur C., Wang E., Ramakrishnan V., Wang X. Y., Bear H. D., Marincola F. M., Manjili M. H., A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Research and Treatment 2012 131 3 871 880 2-s2.0-79953698479 10.1007/s10549-011-1470-x
60. Pulukuri S. M., Rao J. S., Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. International Journal of Oncology 2005 26 4 863 871 2-s2.0-22844437430
61. Yang D., Torres C. M., Bardhan K., Zimmerman M., McGaha T. L., Liu K., Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo. The Journal of Immunology 2012 188 9 4441 4449 10.4049/jimmunol.1103035
62. Chen M. Y., Liao W. S., Lu Z., Bornmann W. G., Hennessey V., Washington M. N., Rosner G. L., Yu Y., Ahmed A. A., Bast Jr R. C., Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011 117 19 4424 4438 10.1002/cncr.26073
63. Bao L., Dunham K., Lucas K., MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunology, Immunotherapy 2011 60 9 1299 1307 2-s2.0-79957528087 10.1007/s00262-011-1037-z
64. Almstedt M., Blagitko-Dorfs N., Duque-Afonso J., Karbach J., Pfeifer D., Jäger E., Lübbert M., The DNA demethylating agent 5-aza-2'- deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Research 2010 34 7 899 905 2-s2.0-77952952304 10.1016/j.leukres.2010.02.004
65. Toor A. A., Payne K. K., Chung H. M., Sabo R. T., Hazlett A. F., Kmieciak M., Sanford K., Williams D. C., Clark W. B., Roberts C., McCarty J., Manjili M. H., Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. British Journal of Haematology 2012 158 6 700 711 10.1111/j.1365-2141.2012.09225.x
66. Re-expression of ER in Triple Negative Breast Cancers.
67. Geutjes E. J., Tian S., Roepman P., Bernards R., Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Research and Treatment 2012 131 3 809 818 2-s2.0-79953266176 10.1007/s10549-011-1477-3
68. Truneh A., Albert F., Golstein P., Schmitt-Verhulst A. M., Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 1985 313 6000 318 320 2-s2.0-0021958592 (Pubitemid 15151988)
69. Tuttle T. M., Inge T. H., Bethke K. P., McCrady C. W., Pettit G. R., Bear H. D., Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Research 1992 52 3 548 553 2-s2.0-0026573371
70. Chatila T., Silverman L., Miller R., Geha R., Mechanisms of T cell activation by the calcium ionophore ionomycin. Journal of Immunology 1989 143 4 1283 1289 2-s2.0-0024328679 (Pubitemid 19211362)
71. Kazanietz M. G., Lewin N. E., Gao F., Pettit G. R., Blumberg P. M., Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Molecular Pharmacology 1994 46 2 374 379 2-s2.0-0028167842
72. Chatila T., Silverman L., Miller R., Geha R., Mechanisms of T cell activation by the calcium ionophore ionomycin. Journal of Immunology 1989 143 4 1283 1289 2-s2.0-0024328679 (Pubitemid 19211362)
73. Kazanietz M. G., Lewin N. E., Gao F., Pettit G. R., Blumberg P. M., Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Molecular Pharmacology 1994 46 2 374 379 2-s2.0-0028167842
74. Morales J. K., Kmieciak M., Knutson K. L., Bear H. D., Manjili M. H., GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Research and Treatment 2010 123 1 39 49 2-s2.0-77955771348 10.1007/s10549-009-0622-8
75. Gehrmann M., Marienhagen J., Eichholtz-Wirth H., Fritz E., Ellwart J., Jäättelä M., Zilch T., Multhoff G., Dual function of membrane-bound heat shock protein 70 (Hsp70), Bag-4, and Hsp40: protection against radiation-induced effects and target structure for natural killer cells. Cell Death and Differentiation 2005 12 1 38 51 2-s2.0-11844259397 10.1038/sj.cdd.4401510 (Pubitemid 40090027)
76. Schmid T. E., Multhoff G., Radiation-induced stress proteinsthe role of heat shock proteins (HSP) in anti- tumor responses. Current Medicinal Chemistry 2012 19 12 1765 1770 10.2174/092986712800099767
77. Gasser S., Orsulic S., Brown E. J., Raulet D. H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005 436 7054 1186 1190 2-s2.0-24144443517 10.1038/nature03884 (Pubitemid 41232299)
78. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M. C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F. J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J. P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., André F., Delaloge S., Tursz T., Kroemer G., Zitvogel L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine 2007 13 9 1050 1059 2-s2.0-34948820602 10.1038/nm1622 (Pubitemid 47517504)
79. Fang H., Wu Y., Huang X., Wang W., Ang B., Cao X., Wan T., Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response. The Journal of Biological Chemistry 2011 286 35 30393 30400 10.1074/jbc.M111.266528
80. Kim J. Y., Son Y. O., Park S. W., Bae J. H., Joo S. C., Hyung H. K., Chung B. S., Kim S. H., Kang C. D., Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Experimental and Molecular Medicine 2006 38 5 474 484 2-s2.0-33750725084 (Pubitemid 44704045)
81. Aguirre-Ghiso J. A., Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer 2007 7 11 834 846 2-s2.0-35548936833 10.1038/nrc2256 (Pubitemid 350006258)
82. Chambers A. F., Groom A. C., MacDonald I. C., Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer 2002 2 8 563 572 2-s2.0-0036674501 10.1038/nrc865 (Pubitemid 37328923)
83. Goss P., Allan A. L., Rodenhiser D. I., Foster P. J., Chambers A. F., New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? Acta Pathologica, Microbiologica et Immunologica 2008 116 7-8 552 568 2-s2.0-52049084581 10.1111/j.1600-0463.2008. 001059.x
84. Karrison T. G., Ferguson D. J., Meier P., Dormancy of mammary carcinoma after mastectomy. Journal of the National Cancer Institute 1999 91 1 80 85 2-s2.0-0033528092 (Pubitemid 29042447)
85. Almog N., Molecular mechanisms underlying tumor dormancy. Cancer Letters 2010 294 2 139 146 2-s2.0-77953362501 10.1016/j.canlet.2010.03.004
86. Coller H. A., Sang L., Roberts J. M., A new description of cellular quiescence. PLoS Biology 2006 4 3 0329 0349 2-s2.0-33644984490 10.1371/journal.pbio.0040083
87. Pelayo R., Miyazaki K., Huang J., Garrett K. P., Osmond D. G., Kincade P. W., Cell cycle quiescence of early lymphoid progenitors in adult bone marrow. Stem Cells 2006 24 12 2703 2713 2-s2.0-33846008339 10.1634/stemcells.2006-0217 (Pubitemid 46053008)